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Purpose. In women who reported a weak urinary stream, the eﬃcacy of treatment chosen according to the urodynamic ﬁndings
on pressure-ﬂow study was prospectively evaluated. Materials and Methods. Twelve female patients with maximum ﬂow rates of
10mL/sec or lower were analyzed in the present study. At baseline, all underwent pressure-ﬂow study to determine the degree
of bladder outlet obstruction (BOO) and status of detrusor contractility on Sch¨ afer’s diagram. Distigmine bromide, 10mg/d,
was given to the patients with detrusor underactivity (DUA) deﬁned as weak/very weak contractility, whereas urethral dilatation
was performed using a metal sound for those with BOO (linear passive urethral resistance relation 2–6). Treatment eﬃcacy was
evaluated using the International Prostate Symptom Score (IPSS), uroﬂowmetry, and measurement of postvoid residual urine
volume. Some patients underwent pressure-ﬂow study after treatment. Results. Urethral dilatation was performed for six patients
with BOO, while distigmine bromide was given to the remaining six showing DUA without BOO. IPSS, QOL index, and the
urinary ﬂow rate were signiﬁcantly improved in both groups after treatment. All four of the patients with BOO and one of the
three with DUA but no BOO who underwent pressure-ﬂow study after treatment showed decreased degrees of BOO and increased
detrusor contractility, respectively. Conclusions. Both BOO and DUA cause a decreased urinary ﬂow rate in women. In the short-
term, urethral dilatation and distigmine bromide are eﬃcacious for female patients with BOO and those with DUA, respectively.
Copyright © 2009 Yoshinori Tanaka et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Pressure-ﬂow study is the only method to simultaneously
evaluate bladder outlet obstruction (BOO) and detrusor
contractility [1]. It has been demonstrated that there are two
major causes of decreased urinary ﬂow rate in women; BOO
and detrusor underactivity (DUA), similar to men [2, 3].
Alpha 1 blockers [4] or urethral dilatation may be eﬃcacious
by reducing the degree of BOO in women. On the other
hand, bethanechol chloride and distigmine bromide may
increase the urinary ﬂow rate through improved detrusor
contractility in female patients with DUA. However, few
studies have investigated the eﬃcacy of treatment strategies
decided according to the cause of the decreased urinary ﬂow
rate in women.
In the present study, we performed a pressure-ﬂow study
for female patients who reported a weak urinary stream
to determine the cause of the decreased urinary ﬂow rate.
According to the cause, BOO, or DUA, urethral dilatation or
medical therapy with distigmine bromide was chosen, and
the treatment eﬃcacy was prospectively evaluated.
2.MaterialsandMethods
Female patients who visited Furuya Hospital because of
awareness of a weak urinary stream were investigated in the
present study. Women having obvious neurogenic bladder,
pelvic organ prolapsed, and a history of surgery of the
pelvic organs were excluded from the study. Patients received2 Advances in Urology
examination with the International Prostate Symptom Score
(IPSS), QOL index, uroﬂowmetry, and measurement of
postvoid residual urine volume (PVR). Twelve patients with
maximum ﬂow rates (Qmax) of 10mL/sec or lower were
analyzed in the present study. Pressure-ﬂow study was
performed after the risks and beneﬁts of the study were
explained and the patients gave oral informed consent.
The method used for the pressure-ﬂow study was previ-
ouslyreported[5].Urodynamicparametersusedinthestudy
were based on the standard terminology of the International
Continence Society [6]. The urethral resistance factor [7]
and maximum watts factor [8] were automatically calculated
using a computer [9]. Since there is no consensus on
how to properly determine BOO and detrusor contractility
in women, we employed Sch¨ afer’s diagram [10], which is
basically applicable only to men, for female subjects. A linear
passive urethral resistance relation (LinPURR) of grade 2 or
more and weak/very weak contractility were deﬁned as BOO
and DUA, respectively.
The treatment strategy was chosen according to the
urodynamic ﬁndings. For patients with BOO, the urethra
was dilated using a metal sound up to 28 French for 10–15
minutes under urethral anesthesia with 2% xylocaine jelly.
For patients with DUA without BOO, distigmine bromide
(10mg/d) was prescribed.
After two weeks of urethral dilatation and four weeks of
distigmine bromide treatment, the short-term eﬃcacy was
evaluated using the IPSS, QOL index, uroﬂowmetry, and
measurement of PVR. Four of the six patients treated by
urethral dilatation and one of the three women treated with
distigmine bromide agreed with examination by pressure-
ﬂow study after treatment.
Statistical comparisons of unpaired and paired groups
were done using the Mann-Whitney U test and Wilcoxon
signed-rank test, respectively. Statistical signiﬁcance was
assumed at P<. 05.
3. Results
Of the 12 women for whom pressure-ﬂow study was per-
formed, six had BOO (Table 1). They had normal detrusor
contractility except one with weak detrusor contractility.
All of the remaining six patients without BOO had weak
detrusor contractility according to Sch¨ afer’s diagram. The
mean age of patients without BOO was signiﬁcantly higher
thanthatofpatientswithBOO.Theurethralresistancefactor
in patients with BOO was signiﬁcantly higher than that of
those without BOO by deﬁnition. On the other hand, the
maximum watts factor was signiﬁcantly lower in patients
without BOO than in those with it. There were no signiﬁcant
diﬀerences in the IPSS, QOL index, urinary ﬂow rate, and
PVR at baseline between patients with and without BOO.
In women with BOO, urethral dilatation signiﬁcantly
improved the IPSS, QOL index, urinary ﬂow rate, and
PVR (Table 2). The urethral resistance factor was decreased
from 53.2 to 20.1cm of water, although it did not reach
statistical signiﬁcance. Pressure-ﬂow study after treatment
demonstrated that all had a decreased grade of LinPURR
(Table 4). In the women without BOO, distigmine bromide
signiﬁcantly improved the IPSS, QOL index, and urinary
ﬂow rate (Table 3). The maximum watts factor was slightly
i n c r e a s e df r o m6 . 1t o8 . 9 W / m 2, but the increase did not
reach statistical signiﬁcance because of small number of
patients. Pressure-ﬂow study after treatment demonstrated
that one patient had improvement of detrusor contractility
from weak to normal (Table 4). No change in the grade
of LinPURR was observed in patients taking distigmine
bromide nor were any obvious side eﬀects observed during
their drug therapy.
4. Discussion
There are few reports in which the causes of diﬃculty on
urination of female patients were evaluated by urodynamics
including pressure-ﬂow study. Wheeler Jr. et al. [2]r e p o r t e d
that the major cause of urinary retention or a large volume
of PVR was poor detrusor contractility. On the other hand,
Massey and Abrams [3] reported in their retrospective study
evaluating urodynamic results of 5948 female patients that
diﬃculty on urination in women was mainly induced by
DUA because only 163 patients (2.74%) had BOO. In the
present study, half of the female patients with a decreased
urinary ﬂow rate had BOO, mostly without DUA, in the
pressure-ﬂow study. On the other hand, all patients without
BOO exhibited DUA with a lower maximum watts factor
than those with BOO. Thus, there were two main causes
of the decreased urinary ﬂow rate in female patients: BOO
and DUA. Since there were no diﬀerences in the IPSS, QOL
index, urinary ﬂow rate, and PVR between patients with
and without BOO, except age at baseline, it was diﬃcult to
determine the existence of BOO only by clinical parameters.
There are several causes of BOO in female patients,
including urethral stricture, meatal stenosis, atrophic
changes of the vaginal wall, urethral caruncle, extramural
compression by pelvic masses, and iatrogenic causes after
operation for stress urinary incontinence [3]. Kuo [11]
reported that 207 women with BOO were categorized
into ﬁve groups on the basis of the videourodynamic
ﬁndings. The study revealed bladder neck obstruction in 18
patients (9%), urethral sphincter obstruction in 56 (27%),
pelvic ﬂoor muscle obstruction in 106 (51%), pelvic organ
prolapse in 13 (6%), and urethral stricture in 14 (7%).
It has been reported that women with BOO are treated
with urethral dilatation, otis urethrotomy, intermittent self-
catheterization, excision of the caruncle, and surgery for
extramural obstruction [3]. Diokno et al. [12]a n dA x e l r o d
and Blaivas [13] reported that female patients with bladder
neck obstruction were successfully treated with transurethral
neck incision. Botulinum A toxin injection into the urethral
sphincter also had potential to decrease urethral resistance
and improve voiding [14]. In our study, the causes of
BOO were unclear because of lack of videourodynamic
evaluation urethral dilatation using a metal sound improved
lower urinary tract symptoms (LUTSs) and the urinary
ﬂow rate in female patients with BOO. Although it did not
reach statistical signiﬁcance, the urethral resistance factor
was reduced. Posttreatment pressure-ﬂow study showed that
LinPURR was improved by two to three grades. Thus,Advances in Urology 3
Table 1: Baseline parameters in patients with and without bladder outlet obstruction.
Parameters Without BOO(1) With BOO P-value(2)
(n = 6) (n = 6)
Age 69.5 (8.0)(3) 46.0 (12.4) .025
IPSS 17.8 (8.3) 20.0 (7.6) .471
QOL index 5.3 (0.5) 5.7 (0.5) .337
Uroﬂowmetry
Voided volume (mL) 223.7 (54.6) 176.7 (95.0) .423
Maximum ﬂow rate (mL/sec) 8.1 (2.3) 6.8 (3.2) .379
Average ﬂow rate (mL/sec) 3.7 (1.0) 3.1 (1.7) .471
Postvoid residual urine volume (mL) 71.3 (69.4) 236.3 (170.5) .078
Pressure ﬂow studies
Maximum ﬂow rate (mL/sec) 8.3 (2.3) 5.8 (1.5) .093
Pressure at maximum ﬂow (cm water) 23.2 (11.6) 88.0 (20.2) .004
Urethral resistance factor (cm water) 15.4 (8.0) 52.9 (11.3) .004
Maximum watts factor (W/m2) 5.2 (2.1) 12.4 (2.9) .004
(1)BOO, bladder outlet obstruction
(2)Mann-Whitney U test
(3)Mean (standard deviation).
Table 2: Change in parameters after urethral dilatation in patients with bladder outlet obstruction.
Parameters Pretreatment Posttreatment P-value(1)
Clinical parameters (n = 6)
IPSS 20.0 (7.6)(2) 4.8 (0.8) .028
QOL index 5.7 (0.5) 2.2 (1.0) .028
Uroﬂowmetry
Voided volume (mL) 176.7 (95.0) 222.0 (54.1) .028
Maximum ﬂow rate (mL/sec) 6.8 (3.2) 13.9 (4.9) .028
Average ﬂow rate (mL/sec) 3.1 (1.7) 7.9 (3.1) .028
Postvoid residual urine volume (mL) 236.3 (170.5) 80.8 (102.0) .028
Pressure ﬂow studies (n = 4)
Maximum ﬂow rate (mL/sec) 5.2 (1.5) 14.2 (3.4) .068
Pressure at maximum ﬂow (cm water) 80.5 (18.0) 49.8 (18.9) .068
Urethral resistance factor (cm water) 53.2 (14.2) 20.1 (4.9) .068
Maximum watts factor (W/m2) 11.4 (2.8) 11.2 (3.7) <.999
(1)Wilcoxon signed-rank test
(2)Mean (standard deviation).
urethral dilatation was an eﬀective treatment method for
female patients with BOO, although the durability was not
evaluated in this study.
Wheeler Jr. et al. [2] reported that weak detrusor
contractility was induced by diabetes mellitus, multiple
sclerosis, disc hernia, tumors in the central nervous system,
total abdominal hysterectomy, and psychosocial problems.
ThecausesofDUAwereunclearinourstudybecausewomen
with obvious neurogenic bladder and a history of pelvic
surgerywere excluded from the study. Since the patients with
DUA but no BOO were signiﬁcantly older than those with
BOO, aging of the detrusor muscle might be involved in the
development of DUA.
It has been demonstrated that distigmine bromide
increasesdetrusorcontractilitybyinactivatingcholinesterase
and maintaining cholinergic stimulation. Indeed, in poor
malevoidersaftertransurethralresectionoftheprostatewith
DUA proven by pressure-ﬂow study, distigmine bromide
improved LUTS and the urinary ﬂow rate by increasing
detrusor contractility [4]. In the present study, 10mg of
distigmine bromide also improved LUTS and the ﬂow rate in
femalepatientswithDUAwasprovenbypressure-ﬂowstudy.
Although it did not reach statistical signiﬁcance because
of small number of patients, the maximum watts factor
was slightly increased after administration of distigmine
bromide. Thus, distigmine bromide may be considered for
women with DUA with care of development of cardiovascu-
lar eﬀects such as ﬂushing, palpitation, and blood pressure
elevation and gastrointestinal eﬀects such as nausea, vomit-
ing, diarrhea, and clumps, although the available studies do4 Advances in Urology
Table 3: Change in parameters after distigmine bromide treatment in patients without bladder outlet obstruction.
Parameters Pretreatment Posttreatment P-value(1)
Clinical parameters (n = 6)
IPSS 17.8 (8.3)(2) 5.2 (4.8) .028
QOL index 5.3 (0.5) 1.3 (1.0) .028
Uroﬂowmetry
Voided volume (mL) 223.7 (54.6) 245.7 (124.6) .753
Maximum ﬂow rate (mL/sec) 8.1 (2.3) 13.1 (4.3) .046
Average ﬂow rate (mL/sec) 3.7 (1.0) 6.8 (1.8) .028
Postvoid residual urine volume (mL) 71.3 (69.4) 45.0 (61.0) .249
Pressure ﬂow studies (n = 3)
Maximum ﬂow rate (mL/sec) 8.3 (2.9) 13.3 (0.6) .109
Pressure at maximum ﬂow (cm water) 31.0 (5.6) 33.0 (8.7) <.999
Urethral resistance factor (cm water) 20.2 (1.3) 15.8 (2.1) .109
Maximum watts factor (W/m2) 6.1 (2.5) 8.9 (0.2) .109
(1)Wilcoxon signed-rank test
(2)Mean (standard deviation).
Table 4: Changes in degree of bladder outlet obstruction and status
of detrusor contractility after treatments.
(a) Urethral dilatation in patients with BOO(1) (n = 4).
LinPURR(2) (Detrusor contractility)
Pre-treatment Post-treatment
Patient 1 degree 4 (Normal) degree 2 (Strong)
Patient 2 degree 4 (Normal) degree 2 (Normal)
Patient 3 degree 4 (Normal) degree 1 (Normal)
Patient 4 degree 3 (Weak) degree 1 (Weak)
(b) Distigmine bromide in patients without BOO (n = 3).
Detrusor contractility (LinPURR)
Pre-treatment Post-treatment
Patient 1 Weak (degree 1) Normal (degree 1)
Patient 2 Weak (degree 1) Weak (degree 1)
Patient 3 Weak (degree 1) Weak (degree 1)
(1)BOO, bladder outlet obstruction
(2)LinPURR, linear passive urethral resistance relation.
not strongly support the use of parasympathomimetics for
treating DUA because of inconsistent results [15].
Several criteria for female BOO have been proposed [16–
19]. Blaivas and Groutz [19]c o n s t r u c t e daB O On o m o g r a m
for women with LUTS in 2000. Since our study was per-
formed before publication of the nomogram, we could not
use it. If the Blaivas and Groutz nomogram had been applied
to our patients, ﬁve of the six patients with BOO on Sch¨ afer’s
diagram would have been categorized into moderate or
severe obstruction on the nomogram and all six patients
without BOO as having no or mild obstruction. Thus, since
most of the patients treated with urethral dilatation had
moderate or severe obstruction on the Blaivas and Groutz
nomogram, selection of the treatment strategy in this study
was thought to be suitable.
5. Conclusions
The two major causes of decreased urinary ﬂow rate in
women were BOO and DUA. In the short-term, urethral
dilatation and distigmine bromide improved BOO and
detrusor contractility in patients with BOO and DUA,
respectively.
Abbreviations
BOO: Bladder outlet obstruction
DUA: Detrusor underactivity
IPSS: The International Prostate Symptom Score
PVR: Postvoid residual urine volume
Qmax: Maximum ﬂow rate
LinPURR: Linear passive urethral resistance relation
LUTS: Lower urinary tract symptoms.
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